117 related articles for article (PubMed ID: 10505672)
1. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea.
Boelaert JR; Sperber K; Piette J
AIDS Res Hum Retroviruses; 1999 Sep; 15(14):1241-7. PubMed ID: 10505672
[TBL] [Abstract][Full Text] [Related]
2. The additive in vitro anti-HIV-1 effect of chloroquine, when combined with zidovudine and hydroxyurea.
Boelaert JR; Sperber K; Piette J
Biochem Pharmacol; 2001 Jun; 61(12):1531-5. PubMed ID: 11377382
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl]adenine, and 9-[2-(phosphonylmethoxy)propyl]adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates.
Palmer S; Shafer RW; Merigan TC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2046-50. PubMed ID: 10428934
[TBL] [Abstract][Full Text] [Related]
4. The anti-HIV-1 activity of chloroquine.
Savarino A; Gennero L; Sperber K; Boelaert JR
J Clin Virol; 2001 Feb; 20(3):131-5. PubMed ID: 11166661
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea: mechanisms of HIV-1 inhibition.
Lori F; Lisziewicz J
Antivir Ther; 1998; 3 Suppl 4():25-33. PubMed ID: 10723506
[TBL] [Abstract][Full Text] [Related]
6. The ability of chloroquine to prevent tat-induced cytokine secretion by monocytes is implicated in its in vivo anti-human immunodeficiency virus type 1 activity.
Rayne F; Vendeville A; Bonhoure A; Beaumelle B
J Virol; 2004 Nov; 78(21):12054-7. PubMed ID: 15479845
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
Lori F; Lisziewicz J
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S193-7. PubMed ID: 10860905
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyurea reduces the 50% inhibitory concentration of didanosine in HIV-infected cells.
Rana KZ; Simmons KA; Dudley MN
AIDS; 1999 Oct; 13(15):2186-8. PubMed ID: 10546884
[No Abstract] [Full Text] [Related]
9. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.
Savarino A; Lucia MB; Rastrelli E; Rutella S; Golotta C; Morra E; Tamburrini E; Perno CF; Boelaert JR; Sperber K; Cauda R
J Acquir Immune Defic Syndr; 2004 Mar; 35(3):223-32. PubMed ID: 15076236
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyurea and interleukin-6 synergistically reactivate HIV-1 replication in a latently infected promonocytic cell line via SP1/SP3 transcription factors.
Oguariri RM; Brann TW; Imamichi T
J Biol Chem; 2007 Feb; 282(6):3594-604. PubMed ID: 17150965
[TBL] [Abstract][Full Text] [Related]
11. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.
Hossain MM; Coull JJ; Drusano GL; Margolis DM
Antiviral Res; 2002 Jul; 55(1):41-52. PubMed ID: 12076750
[TBL] [Abstract][Full Text] [Related]
12. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
[TBL] [Abstract][Full Text] [Related]
13. Direct analysis of mitochondrial toxicity of antiretroviral drugs.
Foli A; Benvenuto F; Piccinini G; Bareggi A; Cossarizza A; Lisziewicz J; Lori F
AIDS; 2001 Sep; 15(13):1687-94. PubMed ID: 11546944
[TBL] [Abstract][Full Text] [Related]
14. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
15. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.
Heredia A; Davis C; Redfield R
J Acquir Immune Defic Syndr; 2000 Nov; 25(3):246-55. PubMed ID: 11115955
[TBL] [Abstract][Full Text] [Related]
17. [Decrease of HIV-1 replicative capacity after serial passage in MT-4 cells under conditions of the combined antiretroviral therapy].
Selimova LM; Khanina TA; Galegov GA
Antibiot Khimioter; 2003; 48(6):7-10. PubMed ID: 14558412
[TBL] [Abstract][Full Text] [Related]
18. Stavudine selectively induces apoptosis in HIV type 1-infected cells.
Hashimoto KI; Tsunoda R; Okamoto M; Shigeta S; Baba M
AIDS Res Hum Retroviruses; 1997 Jan; 13(2):193-9. PubMed ID: 9007205
[TBL] [Abstract][Full Text] [Related]
19. Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.
Klein MB; Campeol N; Lalonde RG; Brenner B; Wainberg MA
AIDS; 2003 May; 17(7):1001-8. PubMed ID: 12700449
[TBL] [Abstract][Full Text] [Related]
20. Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine.
Gao WY; Zhou BS; Johns DG; Mitsuya H; Yen Y
Biochem Pharmacol; 1998 Jul; 56(1):105-12. PubMed ID: 9698094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
